Clinical trials: Clopidogrel, completed
Acute Ischemic Stroke
A Study to Evaluate Safety and PK of Multiple Doses of LT3001 Drug Product and Drug-drug Interaction in Healthy Subjects
This Phase 1 study is planned to establish the clinical safety and pharmacokinetics profile of multiple dose of LT3001 drug product and to investigate drug interactions of LT3001 with potential concomitant medications in healthy…
- Trial name
- NCT04809818
- Testing
- LT3001 drug product, Aspirin, Clopidogrel
- Where
- United States
- Volunteers
- 65 people, healthy volunteers welcome
- Sponsor
- Lumosa Therapeutics Co., Ltd.
Platelet Activation Testing Before/After Anti-platelet Therapy, Healthy
The Accuracy Of A Novel Platelet Activity Assay In Humans On Antiplatelet Agents: Pharmacodynamics And Comparison With Light Transmission Aggregometry
The purpose of this study is to test a novel diagnostic immunoassay of platelet function and compare it to the current gold standard platelet function assay by testing the response to aspirin and clopidogrel in a group of healthy…
- Trial name
- NCT04822363
- Testing
- Aspirin, Clopidogrel
- Where
- United States
- Volunteers
- 112 people, healthy volunteers welcome
- Sponsor
- Beth Israel Deaconess Medical Center
Aneurysm Cerebral, Endovascular Procedures
Optimal Duration of Dual Antiplatelet Therapy After Stent-assisted Coiling
Comparison of duration of dual antiplatelet therapy after stent-assisted coiling of unruptured intracranial aneurysms
- Trial name
- NCT05257824
- Testing
- Aspirin 100mg, Clopidogrel 75mg
- Where
- 8 sites in South Korea
- Volunteers
- 528 people
- Sponsor
- Seoul National University Bundang Hospital
Atrial Fibrillation
Left Atrial Appendage CLOSURE in Patients With Atrial Fibrillation Compared to Medical Therapy
The study goal is to determine the clinical benefit of percutaneous catheter-based left atrial appendage (LAA) closure in patients with non-valvular atrial fibrillation (NVAF) at high risk of stroke (CHA2DS2-VASc Score ≥2) as…
- Trial name
- CLOSURE-AF (NCT03463317)
- Testing
- CE-mark approved LAA closure devices, Acetylsalicylic acid, Clopidogrel
- Where
- 42 sites in Germany
- Volunteers
- 912 people
- Sponsor
- Charite University, Berlin, Germany
Unruptured Intracranial Aneurysm, Flow Diverter
Tirofiban for Reduction of Thromboembolic Events in Endovascular Unruptured Aneurysm Repair
To explore whether administering tirofiban in stent-assisted coiling/flow diverting treatments for participants with unruptured intracranial aneurysms can reduce new ischemic lesions on postoperative DWI sequences compared to…
- Conditions
- Unruptured Intracranial Aneurysm, Flow Diverter, Stent-assisted Coiling, Thromboembolic Events
- Trial name
- TEAR (NCT06238115)
- Testing
- Tirofiban, aspirin, clopidogrel
- Where
- China
- Volunteers
- 192 people
- Sponsor
- Beijing Tiantan Hospital
Acute Ischemic Stroke
Intravenous Thrombolysis With rhTNK-tPA for Acute Non-large Vessel Occlusion in Extended Time Window
This study is designed to evaluate the efficacy of IV rhTNK-tPA between 4.5 to 24 hours from symptom onset in patients presenting with a non-large vessel occlusion ischemic stroke.
- Trial name
- OPTION (NCT05752916)
- Testing
- rhTNK-tPA, Antiplatelet Agents
- Where
- China
- Volunteers
- 570 people
- Sponsor
- Xuanwu Hospital, Beijing
Coronary Artery Disease, Myocardial Ischemia
Dual Anti-Platelet Therapy in Patients With Coronary Multi-Vessel Disease (DAPT-MVD)
This study is a prospective, multicenter, parallel, open-label, randomized, controlled, superiority trial. It is planned to recruit 8,250 patients with multi-vessel disease(MVD), and the patients will be followed-up for at least…
- Conditions
- Coronary Artery Disease, Myocardial Ischemia, Acute Coronary Syndrome, Heart Diseases
- Trial name
- NCT04624854
- Testing
- Clopidogrel and aspirin dual-antiplatelet therapy, Aspirin monotherapy
- Where
- 97 sites in China
- Volunteers
- 8,250 people
- Sponsor
- Harbin Medical University
Ischemic Stroke
A Study to Evaluate the Efficacy and Safety of Renexin CR in Patients With Acute Non-cardioembolic Ischemic Stroke
A study to Evaluate the Efficacy and Safety of Renexin CR in patients with Acute Non-cardioembolic Ischemic Stroke
- Trial name
- NCT05445895
- Testing
- Renexin CR 200/160mg, Plavix 75mg
- Where
- South Korea
- Volunteers
- 483 people
- Sponsor
- SK Chemicals Co., Ltd.
Coronary Artery Disease, Clopidogrel Resistance
The Study of CYP2C19 Genotype-Guided Clopidogrel Treatment Models
The study purposed to learn how clopidogrel-based antiplatelet treatment for preventing adverse cardiovascular events after ePCI works in chronic coronary artery disease when guided by personal genetic characteristics for drug…
- Conditions
- Coronary Artery Disease, Clopidogrel Resistance, Coronary Thrombosis, Adverse Cardiac Events
- Trial name
- NCT06665919
- Testing
- CYP2C19 Genotype-Guided Clopidogrel Treatment, CYP2C19 Genotype Guided Antiplatelet Treatment Alternative to Clopidogrel, The Conventional Clopidogrel Treatment
- Where
- 4 sites in Georgia
- Volunteers
- 283 people
- Sponsor
- Vistamedi Ltd.
Kidney Failure, Hemodialysis Fistula Thrombosis
Clopidogrel Prevention of Early Arteriovenous (AV) Fistula Thrombosis
The objective of the study is to determine whether clopidogrel reduces the early failure rate of native AV fistulae. This study was originally registered as NCT00067119 which included two protocols, this one and the GRAFT study)
- Trial name
- FISTULA (NCT03289520)
- Testing
- Clopidogrel
- Where
- 9 sites in United States
- Volunteers
- 877 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Acute Coronary Syndrome
Pharmacokinetic/Pharmacodynamic Study of Vicagrel Capsules and Clopidogrel Tablets in Healthy CYP2C19 Normal Metabolizers
This clinical study will adopt an open-label, randomized, two-crossover design to explore the pharmacokinetic and pharmacodynamic profiles of Vicagrel Capsules and Clopidogrel Tablets in Healthy Subjects with CYP2C19 Normal…
- Trial name
- NCT07067775
- Testing
- Vicagrel Capsules, Clopidogrel Tablets
- Where
- China
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Jiangsu vcare pharmaceutical technology co., LTD
Prolonged DAPT in ACS Patients With Hisk of Both Ischemic and Hemorrhage
Optimal antiPlatelet Therapy for High Bleeding and Ischemic RISK Patients Trial
Current guidelines recommend that patients with ACS undergoing stent implantation might be offered extended DAPT treatment for up to 30 months if necessary.
- Trial name
- OPT-BIRISK (NCT03431142)
- Testing
- Clopidogrel, Clopidogrel+aspirin
- Where
- 103 sites in China
- Volunteers
- 7,758 people
- Sponsor
- Shenyang Northern Hospital
Complement Mediated Glomerular Diseases, Hemolytic Anemia
Investigation of Drug-drug Interaction of HRS-5965 With Clopidogrel and Clarithromycin in Healthy Subjects
The study is being conducted to compare the drug-drug interaction of HRS-5965 with clopidogrel and clarithromycin in healthy subjects.
- Trial name
- NCT07040787
- Testing
- HRS-5965 Capsules, Clopidogrel, Clarithromycin
- Where
- China
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Chengdu Suncadia Medicine Co., Ltd.
Coronary Artery Disease
Tailoring P2Y12 Inhibiting Therapy in Patients Requiring Oral Anticoagulation After PCI
Clopidogrel is the P2Y12 inhibitor of choice in PCI patients requiring OAC. However, concerns have been raised based on the notion that a considerable number of patients may have inadequate response to clopidogrel.
- Trial name
- SWAP-AC-2 (NCT04483583)
- Testing
- Ticagrelor 60mg, Clopidogrel
- Where
- United States
- Volunteers
- 81 people
- Sponsor
- University of Florida
Stent Thrombosis, Myocardial Infarction, Acute
TADCLOT- a Double Blind Randomized Controlled Trial
Compare the safety and efficacy of a twice-daily Clopidogrel regimen vs. Ticagrelor in reducing major adverse events in patients undergoing primary PCI in a double-blind randomized controlled trial.
- Trial name
- TADCLOT (NCT06318481)
- Testing
- Ticagrelor 90 MG, Clopidogrel
- Where
- Pakistan
- Volunteers
- 2,200 people
- Sponsor
- National Institute of Cardiovascular Diseases, Pakistan
Healthy
A Study to Investigate the Interaction Between ACT-246475 and Clopidogrel, Prasugrel, and Ticagrelor in Healthy Subjects
The primary objective of this study is to assess the pharmacodynamic (PD) effects of clopidogrel, prasugrel, and ticagrelor when administered after a single subcutaneous (s.c.) dose of ACT-246475 in healthy male and female…
- Trial name
- NCT03430661
- Testing
- ACT-246475, Clopidogrel, Prasugrel
- Where
- United States
- Volunteers
- 77 people, healthy volunteers welcome
- Sponsor
- Viatris Innovation GmbH
Acute Coronary Syndrome
TicagRelor Or Clopidogrel in Severe and Terminal Chronic Kidney Disease Patients Undergoing PERcutaneous Coronary Intervention for an Acute Coronary Syndrome.
Ticagrelor is a potent and fast-acting P2Y12-ADP receptor antagonist recommended as first-line agent in ACS (2). This drug was associated with a 20% relative reduction in the rate of MACE in ACS patients undergoing PCI compared…
- Trial name
- TROUPER (NCT03357874)
- Testing
- Clopidogrel, Ticagrelor
- Where
- France
- Volunteers
- 259 people
- Sponsor
- Assistance Publique Hopitaux De Marseille
Acute Coronary Syndrome, Coronary Arteriosclerosis
The Elderly ACS II Trial
The objective of this study is to compare reduced-dose prasugrel and standard dose clopidogrel in patients older than 74 years with ACS, including non-ST-elevation (NSTEACS) and ST-elevation (STEMI) patients, undergoing early…
- Conditions
- Acute Coronary Syndrome, Coronary Arteriosclerosis, Myocardial Ischemia, Cardiovascular Diseases
- Trial name
- NCT01777503
- Testing
- prasugrel, Clopidogrel
- Where
- 2 sites in Italy
- Volunteers
- 1,457 people
- Sponsor
- Azienda USL Reggio Emilia - IRCCS
Healthy Subjects
A Clinical Study to Assess the Effect of Clopidogrel on the Pharmacokinetics of Selexipag and Its Active Metabolite in Healthy Male Subjects
The purpose of this study is to evaluate the effect of clopidogrel on the pharmacokinetics of selexipag and its active metabolite (ACT-333679) in healthy male adults (by determining the blood concentrations of selexipag and its…
- Trial name
- NCT03496506
- Testing
- Selexipag, Clopidogrel
- Where
- Belgium
- Volunteers
- 22 people, healthy volunteers welcome
- Sponsor
- Actelion
Cognition Disorder, Stroke
NeuroCognition After Carotid Recanalization
Complete occlusion of the Internal carotid artery (ICA) by atherosclerotic disease (COICA) causes approximately 15%-25% of ischemic strokes in the carotid artery distribution.
- Conditions
- Cognition Disorder, Stroke, Occlusion Carotid
- Trial name
- NIA-SCORE (NCT04219774)
- Testing
- Endovascular intervention, Aspirin and Clopidogrel (maximal medical Therapy)
- Where
- 2 sites in United States
- Volunteers
- 25 people
- Sponsor
- Duke University